Study group | Number of patients | |
---|---|---|
Epithelial ovarian cancer patients | 100 (100%) | |
• median age (range) | 59 (46–87) | |
- sub-type serous epithelial | 54 (54%) | |
• median age (range) | 59 (46–81) | |
- sub-type endometrioid epithelial | 46 (46%) | |
• median age (range) | 59 (49–87) | |
Tumor stage | IA-T1aN0M0 | 5 (5%) |
IB-T1bN0M0 | 7 (7%) | |
IC-T1cN0M0 | 13 (13%) | |
IIA-T2aN0M0 | 8 (8%) | |
IIB-T2bN0M0 | 9 (9%) | |
IIC-T2cN0M0 | 8 (8%) | |
IIIA-T3aN0M0 | 9 (9%) | |
IIIB-T3bN0M0 | 9 (9%) | |
IIIC-T3cN0M0 | 7 (7%) | |
IV(metastases) | 25 (25%) | |
Menopausal status: | ||
- postmenopausal | 100 (100%) | |
Benign ovarian tumor patients | 80 (100%) | |
- type cystis serous | 40 (50%) | |
- type cystis endometriosis | 40 (50%) | |
Median age (range) | 54 (48–68) | |
Menopausal status: | ||
- postmenopausal | 80 (100%) | |
Healthy subjects | 50 (100%) | |
Median age (range) | 55 (47–64) | |
Menopausal status: | ||
- postmenopausal | 50 (100%) |